Skip to content

How radioligand therapy is rewriting cancer care

September 24, 2026 · 16 min

Show notes

In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeutic reach could potentially reshape care for more than 14 million patients worldwide.

We also discuss Curium's push to expand US capacity and scale up at pace, and critically what success could mean for patients with cancer in the years ahead.

This episode is presented in partnership with Curium.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Mike Patterson, CEO North America, Curium

Sabine Brookman-May, VP and Head of Global Clinical Development, Curium

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

All episodes of BioSpace

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.